The prognostic value of the proportion and subtype patterns of intraductal carcinoma of the prostate in patients with de novo metastatic prostate cancer: A propensity score matching study

IntroductionRandomized clinical trials demonstrated improved overall survival in chemotherapy exposed metastatic prostate cancer patients. However, real-world data validating this effect with large scale epidemiological data sets are scarce and might not agree with trials. We tested this hypothesis.Materials and MethodsWe identified de novo metastatic prostate cancer patients within the Surveillance, Epidemiology, and End Results (SEER) database (2014-2015). Kaplan-Meier plots and Cox regression models tested for overall survival differences between chemotherapy-exposed patients vs chemotherapy-naïve patients. All analyses were repeated in propensity-score matched cohorts. Additionally, landmark analyses were applied to account for potential immortal time bias.ResultsOverall, 4295 de novo metastatic prostate cancer patients were identified. Of those, 905 (21.1%) patients received chemotherapy vs 3390 (78.9%) did not. Median overall survival was not reached at 30 months follow-up. Chemotherapy-exposed patients exhibited significantly better overall survival (61.6 vs 54.3%, multivariable HR:0.82, CI: 0.72-0.96, p=0.01) at 30 months compared to their chemotherapy-naïve counterparts. These findings were confirmed in propensity score matched analyses (multivariable HR: 0.77, CI:0.66-0.90, p<0.001). Results remained unchanged after landmark analyses were applied in propensity score matched population.ConclusionsIn this contemporary real-world population-based cohort, chemotherapy for metastatic prostate cancer patients was associated with better overall survival. However, the magnitude of overall survival benefit was not comparable to phase 3 trials.

Download Full-text

Intraductal carcinoma of the prostate in prostate biopsy samples: correlation with aggressive pathological features after radical prostatectomy and prognostic value in high-risk prostate cancer

Asian Journal of Andrology ◽

10.4103/aja.aja_117_19 ◽

2020 ◽

Vol 22 (5) ◽

pp. 519 ◽

Cited By ~ 1

Author(s):

Peng-Fei Shen ◽

Hao Zeng ◽

Sha Zhu ◽

Jin-Ge Zhao ◽

Jun-Ru Chen ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Radical Prostatectomy ◽

Prostate Biopsy ◽

Prognostic Value ◽

Intraductal Carcinoma ◽

Pathological Features ◽

Carcinoma Of The Prostate ◽

High Risk Prostate Cancer ◽

Risk Prostate Cancer

Download Full-text

Propensity score matched comparison of docetaxel and androgen receptor axis-targeted (ARAT) agents in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate (IDC-P).

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.6_suppl.80 ◽

2020 ◽

Vol 38 (6_suppl) ◽

pp. 80-80

Author(s):

Akiyuki Yamamoto ◽

Masashi Kato ◽

Toyonori Tsuzuki ◽

Momokazu Gotoh

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Propensity Score ◽

Patient Characteristics ◽

Intraductal Carcinoma ◽

Castration Resistant Prostate Cancer ◽

Carcinoma Of The Prostate ◽

Castration Resistant ◽

Significant Difference ◽

Docetaxel Group

80 Background: Several studies have reported that intraductal carcinoma of the prostate (IDC-P) is a pathological adverse prognostic factor in patients with prostate cancer. However, the optimal treatment has not been established. The present study aimed to evaluate the efficacy of docetaxel and androgen receptor axis-targeted (ARAT) agents in patients with castration-resistant prostate cancer (CRPC) with IDC-P using a propensity score-matched analysis. Methods: We retrospectively identified 309 patients with CRPC from February 2007 to February 2016. They received initial androgen deprivation therapy (ADT) and after progression to CRPC, they received docetaxel or ARAT (abiraterone or enzalutamide) as the first-line life-prolonging therapy. The primary outcome of interest was OS from the time of CRPC diagnosis. We also investigated PFS from the time of docetaxel or ARAT initiation. Results: Propensity score-matching identified 85 patients in each group. There were no significant differences in patient characteristics between the groups. The median OS in the docetaxel group was 38.2 months versus 58.3 months in the ARAT group (HR 0.57; 95% CI 0.37–0.89; P =.01). Regarding patients with IDC-P, OS was significantly longer in the ARAT group than the docetaxel group (HR 0.48; 95% CI 0.26–0.86; P =.01), and there was no significant difference in each group, as in patients without IDC-P (HR 0.75; 95% CI 0.37–1.52; P =.43). The median PFS in the docetaxel group was 6.7 versus 7.8 months in the ARAT group (HR 0.65; 95% CI 0.45–0.94; P =.02). A multivariate analysis demonstrated that the presence of IDC-P, duration of primary ADT, visceral metastasis, and administration of ARAT as the first treatment for CRPC were independent prognostic factors for OS. Conclusions: Administration of ARAT as the first treatment for CRPC may prolong OS more than that of docetaxel, especially in patients with IDC-P.

Download Full-text

1197: Prognostic Value of Hemoglobin Change after Initiation of Androgen Deprivations Therapy for Newly Diagnosed Metastatic Prostate Cancer: A Multivariate Analysis of Swog 8894

The Journal of Urology ◽

10.1016/s0022-5347(18)33422-0 ◽

2006 ◽

Vol 175 (4S) ◽

pp. 385-386

Author(s):

Tomasz M. Beer ◽

Bryan H. Goldman ◽

Catherine M. Tangen ◽

Lisa B. Bland ◽

Maha Hussain ◽

...

Keyword(s):

Prostate Cancer ◽

Multivariate Analysis ◽

Prognostic Value ◽

Metastatic Prostate Cancer ◽

Newly Diagnosed

Download Full-text

Prognostic value of Onodera’s nutritional index for intermediate- and high-risk gastrointestinal stromal tumors treated with or without tyrosine kinase inhibitors

World Journal of Surgical Oncology ◽

10.1186/s12957-021-02345-9 ◽

2021 ◽

Vol 19 (1) ◽

Author(s):

Feng Wang ◽

Tingting Tao ◽

Heng Yu ◽

Yingying Xu ◽

Zhi Yang ◽

...

Keyword(s):

Propensity Score ◽

Propensity Score Matching ◽

Prognostic Marker ◽

Gastrointestinal Stromal Tumors ◽

Prognostic Value ◽

Kinase Inhibitors ◽

Rank Test ◽

Stromal Tumors ◽

Lymphocyte Ratio ◽

Nutritional Index

Abstract Background Immunoinflammatory and nutritional markers, such as the peripheral blood neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and Onodera’s prognostic nutritional index (OPNI), have gained considerable attention and have been preliminarily revealed as prognostic markers of gastrointestinal stromal tumors (GISTs). Methods In this study, we first investigated the prognostic value of OPNI in GISTs treated with or without TKIs based on the propensity score matching (PSM) method. All of the patients had received surgical resection for primary GIST, and data from 2010 to 2018 were initially and retrospectively identified from our gastrointestinal center. Recurrence-free survival (RFS) was calculated by the Kaplan–Meier method and compared by the log-rank test. Results The patients were divided into groups treated and not treated with TKIs, and we used the propensity score matching method to homogenize their baseline data. Multivariate Cox proportional hazard regression models were applied to identify associations with outcome variables. A total of 563 GISTs were initially chosen, and 280 of them were included for analysis under the inclusion criteria. After PSM, there were 200 patients included. Multivariate analyses identified OPNI as an independent prognostic marker that was associated with primary site, tumor size, mitotic index, tumor rupture, necrosis, and modified NIH risk classification. Low OPNI (< 42.6; HR 0.409; P < 0.001) was associated with worse RFS. Conclusions Preoperative OPNI is a novel and useful prognostic marker for GISTs both treated and not treated with TKIs. Higher NLR and PLR have negative effects on RFS.

Download Full-text

Role of Removed Lymph Nodes on the Prognosis of M0 Small-Bowel Neuroendocrine Tumors: a Propensity Score Matching Analysis from SEER Database

Journal of Gastrointestinal Surgery ◽

10.1007/s11605-021-04994-3 ◽

2021 ◽

Author(s):

Jie-bin Xie ◽

Yue-shan Pang ◽

Xun Li ◽

Xiao-ting Wu

Keyword(s):

Small Bowel ◽

Propensity Score ◽

Lymph Nodes ◽

Propensity Score Matching ◽

Neuroendocrine Tumors ◽

Prognostic Value ◽

Radical Resection ◽

Clinicopathological Characteristics ◽

Seer Database ◽

Resection Group

Abstract Background Current studies on the number of removed lymph nodes (LNs) and their prognostic value in small-bowel neuroendocrine tumors (SBNETs) are limited. This study aimed to clarify the prognostic value of removed LNs for SBNETs. Methods SBNET patients without distant metastasis from 2004 to 2017 in the SEER database were included. The optimal cutoff values of examined LNs (ELNs) and negative LNs (NLNs) were calculated by the X-tile software. Propensity score matching (PSM) was done to match patients 1:1 on clinicopathological characteristics between the two groups. The Kaplan-Meier method with log-rank test and multivariable Cox proportional-hazards regression model were used to evaluate the prognostic effect of removed LNs. Results The cutoff values of 14 for ELNs and 9 for NLNs could well distinguish patients with different prognoses. After 1:1 PSM, the differences in clinicopathological characteristics between the two groups were significantly reduced (all P > 0.05). Removal of more than one LN significantly improved the prognosis of the patients (P < 0.001). The number of lymphatic metastasis in the sufficiently radical resection group (SRR, 3.74 ± 3.278, ELN > 14 and NLN > 9) was significantly more than that in the insufficiently radical resection group (ISRR, 2.72 ± 3.19, ELN < 14 or NLN < 9). The 10-year overall survival (OS) of the SRR was significantly better than that of the ISRR (HR = 1.65, P = 0.001, 95% CI: 1.24–2.19). Conclusion Both ELNs and NLNs can well predict the OS of patients. Systematic removal of more than 14 LNs and more than 9 NLNs can increase the OS of SBNET patients.

Download Full-text